EP 205: From father to biotech founder: Building hope for children with ultra-rare diseases

Value of the Information & Strength of the Argument

The podcast provides valuable insights into the practical challenges of developing gene therapies for ultra-rare diseases, from fundraising and team-building to regulatory hurdles and manufacturing costs. Terry’s personal experience lends authenticity to the discussion, and his arguments are well-reasoned, particularly regarding the need for regulatory flexibility and the impact of policy decisions on rare disease funding. However, the content is largely anecdotal and lacks empirical data or references to scientific literature, which limits its scientific rigor.

Scientific Rigor, Source Quality, Title Accuracy

The podcast is an opinion-based narrative, and while Terry’s expertise is evident, the lack of cited sources reduces its scientific rigor. The title accurately reflects the content, and the discussion is well-structured. The show notes provide a link to a Google Drive file, but no specific scientific references are mentioned. The content is credible due to the speaker’s direct involvement, but it would benefit from supporting evidence.

The title accurately reflects the content, focusing on the founder's journey and the mission of Elpida Therapeutics.

8/10

The podcast features a founder with direct experience in developing gene therapies for ultra-rare diseases, providing credible first-hand insights. However, it is an opinion-based narrative without peer-reviewed citations.

• 00:00Intro to The Genetics Podcast
• 00:58Welcome to Terry
• 01:24The beginning of Terry’s gene therapy journey after his son Michael was diagnosed with SPG50
• 03:24Learning the biotech industry and building a gene therapy team
• 05:17Terry’s experience with learning about gene therapy without a scientific background
• 06:42The process of building a gene therapy in under three years during the COVID-19 pandemic
• 09:30Fundraising through community support and major donors
• 11:06Expanding access of Michael’s gene therapy to children all over the world
• 12:32The creation of Elpida Therapeutics to develop non-commercially viable therapies and adapting to a challenging funding landscape
• 15:24Insight into cost, accessibility, and the role of endpoints and manufacturing
• 20:06Learning from safety events as gene therapy scales and the importance of considering the risk/reward ratio in rare disease
• 23:24Landscape of precision therapeutics available today beyond AAV vectors
• 27:09Designing trials at Elpida to demonstrate efficacy in ultra-rare disease
• 29:24Adapting meaningful endpoints to disease progression and FDA flexibility
• 34:02Background of Priority Review Vouchers and the negative impact of its non-renewal on rare disease funding
• 37:48Finding optimism in rare disease family initiatives and gene therapy successes, and the future of advanced therapeutics
• 41:07How to support the rare disease community and families

• Elpida Therapeutics — Official website of Elpida Therapeutics, the company founded by Terry Pirovolakis.
• Show Notes — Additional show notes and resources provided in the video description.